Chart Industries, Inc. (NYSE:GTLS) Q4 2022 Earnings Call Transcript

In This Article:

Chart Industries, Inc. (NYSE:GTLS) Q4 2022 Earnings Call Transcript February 24, 2023

Operator: Good morning and welcome to the Chart Industries, Inc. 2022 Fourth Quarter and Full-Year Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. The company's release and supplemental presentation was issued earlier this morning. If you have not received the release, you may access it by visiting Chart's website at www.chartindustries.com. A telephone replay of today's broadcast will be available following the conclusion of the call until Friday, March 3, 2023. The replay information is contained in the company's press release. Before we begin, the company would like to remind you that statements made during this call that are not historical facts are forward-looking statements.

Please refer to the information regarding forward-looking statements and risk factors including in the company's earnings release and latest filings with the SEC. The company undertakes no obligation to update publicly or revise any forward-looking statement. I would now like to turn the conference call over to Jill Evanko, Chart Industries CEO. You may begin.

Jillian Evanko: Thank you, Justin. And thanks everybody for joining us this morning. With me today is Joe Brinkman, our CFO. And together, we will walk through the presentation that was released this morning. While the deck has numerous updates that can be reviewed at your convenience, our formal remarks today will focus on our 2023 outlook, our record fourth quarter and full year 2022 results, the current operating environment, numerous tailwinds that both Chart and Howden are experiencing, and the status on the closing of our pending Howden acquisition. Before we get into our 2022 results and how they springboard us into our reiterated 2023 outlook, note that everything included in the supplemental presentation and our formal remarks today relates to continuing operations.

We have reached a preliminary settlement in the Pacific Fertility Clinic litigation matter related to our 2020 divestiture of our Cryobio business. And as noted in the press release, this will be included in discontinued operations. We were very pleased to put this episode from our prior divestiture behind us and resolve these 217 cases. More specifics regarding the settlement will be included in our 10-K filing. Starting on slide 4, we reiterate our Chart standalone outlook for 2023 for sales in the range of $2.1 billion to $2.2 billion. We are confident in this range given our strong visibility and further supported by the five items on the bottom of the slide. First, it is not unusual for project revenue to shift between quarters. We anticipate realizing pushed fourth quarter 2022 revenue in 2023, but we did not increase our outlook for that timing shift.